Identifying New Therapeutics

Published on July 26, 2021

 

UNC Eshelman School of Pharmacy Associate Professor Qisheng Zhang was recently awarded a $2,247,857 grant from the National Cancer Institute to study mutations in lymphomas and leukemias with the goal of identifying new therapeutics.

The four-year grant will support his work, “A high-throughput platform to identify selective allosteric inhibitors of the PLC-g isozymes.” Co-investigators on the study include Eshelman faculty John Sondek and Kenneth Pearce Jr.

“Our goal is to discover selective inhibitors to further understand how hyperactive PLC-g proteins drive cancer and ultimately to develop novel approaches to treat leukemias and lymphomas,” Zhang said.

Read the complete Carolina Story

Related Stories


The Legacy of Pepper Dowd: 50 Years of Philanthropy

‘A Blessing and an Obligation’

Celebrating Native Presence on Campus